Johan Maertens

51.7k total citations · 10 hit papers
384 papers, 20.2k citations indexed

About

Johan Maertens is a scholar working on Infectious Diseases, Epidemiology and Hematology. According to data from OpenAlex, Johan Maertens has authored 384 papers receiving a total of 20.2k indexed citations (citations by other indexed papers that have themselves been cited), including 204 papers in Infectious Diseases, 193 papers in Epidemiology and 121 papers in Hematology. Recurrent topics in Johan Maertens's work include Antifungal resistance and susceptibility (194 papers), Fungal Infections and Studies (156 papers) and Hematopoietic Stem Cell Transplantation (87 papers). Johan Maertens is often cited by papers focused on Antifungal resistance and susceptibility (194 papers), Fungal Infections and Studies (156 papers) and Hematopoietic Stem Cell Transplantation (87 papers). Johan Maertens collaborates with scholars based in Belgium, Germany and Netherlands. Johan Maertens's co-authors include Katrien Lagrou, Oliver A. Cornely, Johan Van Eldere, Thomas J. Walsh, Marc Boogaerts, Jan Verhaegen, Wouter Meersseman, J. Peter Donnelly, Koen Theunissen and Andrew J. Ullmann and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Johan Maertens

366 papers receiving 19.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus

2002 1.9k citations David W. Denning, Johan Maertens et al. profile →
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia

2007 1.3k citations Oliver A. Cornely, Johan Maertens et al. profile →
Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia

2004 644 citations Johan Maertens, Oliver A. Cornely et al. profile →
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

2009 596 citations Bob Löwenberg, Gert J. Ossenkoppele et al. profile →
Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial)

2007 486 citations Oliver A. Cornely, Johan Maertens et al. profile →
Combination Antifungal Therapy for Invasive Aspergillosis

2015 333 citations Kieren A. Marr, Raoul Herbrecht et al. profile →
European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia

2018 246 citations Johan Maertens, Roger J. M. Brüggemann et al. Journal of Antimicrobial Chemotherapy profile →
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial

2021 167 citations Robin K. Avery, Catherine Cordonnier et al. profile →
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial

2021 161 citations Johan Maertens et al. profile →
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

2022 159 citations Johan Maertens, Marinus van Marwijk Kooy et al. Blood profile →

Peers

Countries citing papers authored by Johan Maertens

Since Specialization

Citations

This map shows the geographic impact of Johan Maertens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johan Maertens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johan Maertens more than expected).

Fields of papers citing papers by Johan Maertens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johan Maertens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johan Maertens. The network helps show where Johan Maertens may publish in the future.

Co-authorship network of co-authors of Johan Maertens

This figure shows the co-authorship network connecting the top 25 collaborators of Johan Maertens. A scholar is included among the top collaborators of Johan Maertens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johan Maertens. Johan Maertens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Older matched sibling donor vs young haploidentical donor for older patients with acute myeloid leukemia 2025 ·Blood Advances ·Xavier Poiré, Myriam Labopin, Emmanuelle Polge, Didier Blaise, Patrice Chevallier, Johan Maertens, Nicolaus Kröger, Caroline Besley, Stéphanie Nguyen, Cristina Castilla‐Llorente, Gèrard Socié, Édouard Forcade, Anne Huynh, Igor Wolfgang Blau, Arnon Nagler, Jaime Sanz, Simona Piemontese, Mohamad Mohty, Fabio Ciceri	2
2	Prognostic significance of cytogenetic risk score in patients with secondary acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-matched unrelated donors: a study from the ALWP /EBMT 2025 ·Bone Marrow Transplantation ·Arnon Nagler, (unknown), Sarah Kayser, (unknown), Nicolaus Kröger, Matthias Stelljes, Johan Maertens, (unknown), Igor Wolfgang Blau, (unknown), Péter Reményi, Tobias Gedde‐Dahl, Gesine Bug, Didier Blaise, Ali Bazarbachi, Jordi Esteve, Mohamad Mohty, (unknown)	0
3	Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy, from the European Conference on Infections in Leukaemia (ECIL-10) 2025 ·Leukemia ·Simone Cesaro, Per Ljungman, Małgorzata Mikulska, Hans H. Hirsch, David Navarro, (unknown), Varun Mehra, Jan Styczyński, Francesco Marchesi, José Luís Piñana, Gernot Beutel, Hermann Einsele, Johan Maertens, Rafael de la Cámara, (unknown)	2
4	Meta-pharmacokinetic analysis of posaconazole following dosing of oral suspension, delayed-release tablet, and intravenous infusion in patients vs. healthy volunteers: Impact of clinical characteristics and race 2023 ·International Journal of Antimicrobial Agents ·Lu Chen, Elke H. J. Krekels, Yalin Dong, Limei Chen, Johan Maertens, Nicole M. A. Blijlevens, Catherijne A. J. Knibbe, Roger J. M. Brüggemann	2
5	Gut microbiota alterations induced by intensive chemotherapy in acute myeloid leukaemia patients are associated with gut barrier dysfunction and body weight loss 2023 ·Clinical Nutrition ·Sarah A. Pötgens, (unknown), Violaine Havelange, Fuyong Li, Audrey M. Neyrinck, N. Neveux, Johan Maertens, Jens Walter, Hélène Schoemans, Nathalie M. Delzenne, Laure B. Bindels	15
6	Urine Aspergillus Antigen Detection to Screen for Invasive Aspergillosis in at-Risk Patients Treated for Hematologic Malignancies 2022 ·Transplantation and Cellular Therapy ·Robina Aerts, Kausik Datta, Kieren A. Marr, Johan Maertens	1
7	Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9) 2022 ·Leukemia ·Simone Cesaro, Per Ljungman, Małgorzata Mikulska, Hans H. Hirsch, Marie von Lilienfeld‐Toal, Catherine Cordonnier, Sylvain Meylan, Varun Mehra, Jan Styczyński, Francesco Marchesi, Caroline Besson, Fausto Baldanti, (unknown), Gernot Beutel, H. Einsele, Élie Azoulay, Johan Maertens, Rafael de la Cámara, (unknown), Livio Pagano	63
8	Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT 2022 ·Bone Marrow Transplantation ·Arnon Nagler, (unknown), Jacques‐Emmanuel Galimard, Myriam Labopin, Nicolaus Kröger, Gèrard Socié, Tobias Gedde‐Dahl, Victoria Potter, Thomas Schroeder, Uwe Platzbecker, Arnold Ganser, Didier Blaise, Urpu Salmenniemi, Johan Maertens, Charles Craddock, Hélène Labussière‐Wallet, Ibrahim Yakoub‐Agha, Bipin N. Savani, Mohamad Mohty	5
9	Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) 2022 ·Leukemia ·Georg Maschmeyer, Lars Bullinger, Carolina García‐Vidal, Raoul Herbrecht, Johan Maertens, Pierantonio Menna, Livio Pagano, Anne Thiebaut‐Bertrand, Thierry Calandra	34
10	Safety and efficacy of intravenously administered cidofovir in adult haematopoietic cell transplant recipients: a retrospective multicentre cohort study 2021 ·Journal of Antimicrobial Chemotherapy ·Anat Stern, Carolyn D. Alonso, Carolina García‐Vidal, Celia Cardozo, Monica A. Slavin, Michelle K. Yong, (unknown), (unknown), Robin K. Avery, Philipp Koehler, Christof Scheid, Oliver A. Cornely, Johan Maertens, (unknown), David J. Epstein, Genovefa A. Papanicolaou, Dionysios Neofytos	12
11	The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia 2020 ·Clinical Cancer Research ·Delphine Verbeke, Sofie Demeyer, Cristina Prieto, Charles E. de Bock, Jolien De Bie, Olga Gielen, Kris Jacobs, Nicole Mentens, Bronte Manouk Verhoeven, Anne Uyttebroeck, Nancy Boeckx, Kim De Keersmaecker, Johan Maertens, Heidi Segers, Jan Cools	21
12	Variable Correlation between Bronchoalveolar Lavage Fluid Fungal Load and Serum-(1,3)-β-d-Glucan in Patients with Pneumocystosis—A Multicenter ECMM Excellence Center Study 2020 ·Journal of Fungi ·Toine Mercier, (unknown), Maud Gits‐Muselli, Samia Hamane, Juergen Prattes, Harald H. Kessler, Ivana Mareković, (unknown), Jörg Steinmann, Ulrike Scharmann, Johan Maertens, Katrien Lagrou, Blandine Denis, Stéphane Bretagne, Alexandre Alanio	14
13	Impact of ABO incompatibility on patients’ outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT 2017 ·Haematologica ·Jonathan Canaani, Bipin N. Savani, Myriam Labopin, Xiao‐Jun Huang, Fabio Ciceri, William Arcese, Johanna Tischer, Yener Koç, Benedetto Bruno, Zafer Gülbaş, Didier Blaise, Johan Maertens, Gerhard Ehninger, Mohamad Mohty, Arnon Nagler	31
14	Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG Conditioning 2015 ·Clinical Cancer Research ·Muriel Hannon, Yves Béguin, Grégory Ehx, Sophie Servais, Laurence Seidel, Carlos Graux, Johan Maertens, Tessa Kerre, (unknown), (unknown), Marianne Fillet, (unknown), Évelyne Willems, André Gothot, Stéphanie Humblet‐Baron, Frédéric Baron	24
15	Invasive aspergillosis after kidney transplantation: a monocentric retrospective experience 2015 ·Lirias (KU Leuven) ·Line Heylen, Johan Maertens, Bert Bammens, (unknown), Pieter Evenepoel, Björn Meijers, Maarten Naesens, Dirk Kuypers, Ben Sprangers	1
16	Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison 2008 ·Blood ·Jan J. Cornelissen, Bronno van der Holt, Gregor Verhoef, Mars B. van ’t Veer, Marinus H. J. van Oers, Harry C. Schouten, Gert J. Ossenkoppele, Pieter Sonneveld, Johan Maertens, Marinus van Marwijk Kooy, M Schaafsma, Pierre W. Wijermans, Douwe H. Biesma, Shulamit Wittebol, P.J. Voogt, Joke W. Baars, Pierre Zachée, Leo F. Verdonck, Bob Löwenberg, A. W. Dekker	121
17	Clinical performance of FXG: RESP (Asp+) assay for Pneumocystis jirovecii on respiratory specimens 2008 ·Lirias (KU Leuven) ·Philippe M. Hauser, Katrien Lagrou, (unknown), Cornelia Lass‐Flörl, David S. Perlin, (unknown), Johan Maertens, Michael Hughes, Paul Bowyer, David W. Denning, (unknown)	1
18	Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party 2007 ·Journal of Clinical Oncology ·Christoph Schmid, Myriam Labopin, Arnon Nagler, Martin Bornhäuser, Jürgen Finke, Athanasios Fassas, Liisa Volin, Günhan Gürman, Johan Maertens, Pierre Bordigoni, Ernst Holler, Gerhard Ehninger, Emmanuelle Polge, Norbert Claude Gorin, (unknown), Vanderson Rocha	360
19	Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? 2007 ·Blood ·Jan J. Cornelissen, Wim L.J. van Putten, Leo F. Verdonck, Matthias Theobald, E Jacky, Simon Daenen, Marinus van Marwijk Kooy, Pierre W. Wijermans, Harry C. Schouten, Peter C. Huijgens, Hans van der Lelie, Martin F. Fey, Augustin Ferrant, Johan Maertens, Aloïs Gratwohl, Bob Löwenberg	345
20	Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications 2007 ·Cancer ·Marisa H. Miceli, Johan Maertens, (unknown), Monica Grazziutti, Gail L. Woods, (unknown), Bart Barlogie, Elias Anaissie	122

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact